An observational study in Congenital Adrenal Hyperplasia, sponsored by University of Alabama at Birmingham. Not yet recruiting at 1 site in United States. Open to participants aged 16 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-14.
Sponsored by University of Alabama at Birmingham · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 50 studies in Adrenal Hyperplasia, Congenital with a site in United States — 10 open to participants now, 14 under way, 4 of them phase 3. Adrenal Hyperplasia, Congenital · United States.
Among the 50 studies in Adrenal Hyperplasia, Congenital with a site in United States, this one is the 9th largest by planned enrollment of the 11 observational ones that give a count, is the only one that started in 2027, is one of 11 observational ones, reaches primary completion later than 7 of the 12 other live ones, and was the 50th registered.
102 studies on the registry are indexed under Adrenal Hyperplasia, Congenital; 29 are open to participants now.
Browse Adrenal Hyperplasia, Congenital studies →10 of the 50 studies in Adrenal Hyperplasia, Congenital with a site in United States are open now. Recruiting first, the newest first:
Mayo Clinic · Sites in United States
Ages 18+
Neurocrine Switzerland GmbH · Sites in United States
Ages 3 mo–47 mo
Johns Hopkins University · Sites in United States
Ages 18+
Crinetics Pharmaceuticals Inc. · Sites in United States, Argentina, Australia and 10 more countries
Ages 1–17
Mayo Clinic · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 20 Adrenal Hyperplasia, Congenital studies recruiting now, 10 (50%) set no upper age limit and 9 (45%) stop at 75 or younger; 7 take children under 18; none take healthy volunteers.
This study: 16 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
50 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 23 · Phase 3 10 · Phase 4 1
First in 1995; this study’s year is marked. 1 started in 2027.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 40 is below the median of 61 across 44 observational studies indexed under Adrenal Hyperplasia, Congenital.
Median enrollment 22 across the 38 interventional studies, 65 across the 11 observational. Of the 30 that completed or were terminated, 19 (63%) have results posted.
This tab as a report to print or save as PDF → With an account.
27 of 50 have an industry lead sponsor. The 10 most frequent:
University of Alabama at Birmingham is the lead sponsor of 1,422 studies on the registry; 277 are open to participants now.
Of its 164 completed or terminated interventional studies of FDA-regulated products, 130 (79%) have results posted.
University of Alabama at Birmingham has 1 study filed under Adrenal Hyperplasia, Congenital — fewer than ten, so there is no comparison to draw.
2 of the studies in Adrenal Hyperplasia, Congenital with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07144163Phase 3Crinetics Pharmaceuticals Inc.A Study to Evaluate Atumelnant in Adults With Congenital Adrenal Hyperplasia | 2027-05 |
| NCT07104812Mayo ClinicImpact of 1 mg Osilodrostat Therapy on Mild Autonomous Cortisol Secretion (MACS) | 2027-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 50 studies in Adrenal Hyperplasia, Congenital with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to implement and evaluate the feasibility and acceptability of a structured healthcare transition program for adolescents and young adults with congenital adrenal hyperplasia (CAH). The study will also examine preliminary effects of the program on transition readiness, disease-specific self-management knowledge, emergency preparedness, continuity of endocrine care, and health-related quality of life as participants transition from pediatric to adult healthcare services.
Study Purpose and Rationale
Congenital adrenal hyperplasia (CAH) is a complex, lifelong endocrine disorder that requires continuous glucocorticoid replacement, stress-dosing during illness, and ongoing monitoring for metabolic, reproductive, and adrenal complications. Adolescents and young adults face substantial challenges maintaining these self-management responsibilities during the transition from pediatric to adult care, a period consistently associated with decreased adherence, reduced clinic attendance, lapses in emergency preparedness, and preventable adrenal crises. Despite these risks, there are currently no structured, evidence-informed transition programs tailored specifically to the needs of individuals with CAH.
The purpose of this study is to evaluate the feasibility, acceptability, and preliminary impact of implementing the Comprehensive Adolescent Healthcare Transition (CAH-T) program for adolescents and young adults with CAH. By combining structured education, readiness assessment, emergency preparedness training, and coordinated transfer to adult endocrinology, this mixed-methods pilot aims to strengthen self-management skills, improve continuity of care, and reduce acute health events. Findings will inform refinement of the CAH-T model and provide essential pilot data needed to support future multi-site implementation.
Objectives and Hypotheses
The overall objective of this mixed-methods feasibility study is to evaluate the implementation and preliminary effectiveness of the Comprehensive Adolescent Healthcare Transition (CAH-T) program for adolescents and young adults with congenital adrenal hyperplasia (CAH). The study aims to determine whether the intervention can be feasibly delivered in a pediatric endocrine clinic, is acceptable to patients and caregivers, and produces early improvements in transition-related outcomes.
The investigators hypothesize that.
Study Design Overview This is a prospective, single-center, single-arm, mixed-methods feasibility and implementation study conducted over 24 months. Adolescents and young adults aged 16-20 years with a diagnosis of CAH, along with one of their caregivers, will participate in a structured transition curriculum integrated into routine endocrine visits. Quantitative measures of readiness, knowledge, quality of life, and emergency preparedness will be collected at baseline, post-intervention, and at 12-month follow-up. Semi-structured interviews with adolescents, caregivers, and providers will be used to contextualize quantitative findings and identify implementation barriers and facilitators.
Population and Sample Size Summary
The study will enroll approximately 15 adolescents and young adults with CAH (ages 16 years and older) and one caregiver per participant from the Children's Hospital of Alabama pediatric endocrinology clinic. This sample size is appropriate for feasibility pilot work in a rare disease population and will provide sufficient data to estimate feasibility metrics, evaluate acceptability, and generate preliminary effect-size estimates for future multi-site trials.
Primary and Secondary Outcomes
Primary Outcomes
Feasibility:
Secondary Outcomes
Emergency Preparedness:
Brief Procedures Summary
Participants will complete a baseline assessment including demographics, CAH knowledge (CAHKAQ),9 transition readiness (STARx/STARx-P),10-12 emergency preparedness, and quality-of-life measures (CAHQL).13 They will then participate in two CAH-T curriculum14 visits embedded in routine endocrine appointments. Age-eligible participants (over 18 years old) will be transferred to adult care following completion of the curriculum and monitored for completion of an adult endocrinology visit. All participants will complete a 12-month follow-up assessment, and emergency care utilization will be recorded for the year preceding enrollment and for the year following intervention completion. Semi-structured interviews will be conducted with adolescents, caregivers, and providers after the program's implementation to explore perceptions of the program's feasibility and acceptability.
Significance / expected impact This study aims to address a significant gap in endocrine transitional care by piloting the first structured, CAH-specific transition program at a U.S. pediatric center. The implementation of CAH-T is expected to improve self-management skills, enhance preparedness for adrenal crises, support a stable quality of life, and increase successful connection to adult endocrinology care. Findings will generate foundational evidence needed to refine the intervention and support future multi-site trials aimed at establishing best practices for transition in rare endocrine disorders.
This population will be recruited from our pediatric endocrinology clinic as available.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
YA Participants
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Other: exposure to healthcare transition protocol
Other: exposure to healthcare transition protocol
Other: exposure to healthcare transition protocol
CAH-T Curriculum Visits CAH-T Visit 1 (V1) CAH-T Visit 1 will occur approximately 3 months after enrollment and will include: * Review of CAH disease management * Stress dosing education * Emergency hydrocortisone instruction * Medical alert education * Teach-back demonstration of emergency injection technique * Discussion of adherence, mental health, fertility/sexual health, bone health, and cardiometabolic health * Introduction to healthcare transition concepts * Development of individualized transition goals For participants aged ≥18 years: * Identification of adult endocrinology provider * Development of transfer plan * Medical summary review/update Relevant educational materials are included in attachments. CAH-T Visit 2 (V2) CAH-T Visit 2 will occur approximately 6 months after enrollment and will include: * Reinforcement of CAH self-management concepts * Review of emergency preparedness * Review of transfer readiness * Finalization of transfer planning
assessment of CAH knowledge
Brief survey of CAH knowledge with Congenital adrenal hyperplasia knowledge questionnaire looking at the treatment of the condition and the mechanism of congenital adrenal hyperplasia. Minimum score 0; Maximum score 44; with 0 indicating lack of knowledge of CAH
Time frame: at baseline, 6 months, and 12 month after initiation of healthcare transition readiness
Self-Management and Transition to Adulthood with Rx (Self-Management and Transition to Adulthood with Rx-parent) questionnaire regarding transtion readiness
This questionnaire assesses patient's readiness for movement to adult healthcare. minimum score of 0, maximum score of 90. 0 indicating patient is not ready for movement to the adult healthcare system.
Time frame: at baseline, 6 months and after 12 month visit
Change in quality of life for patients with CAH
assessment of CAH quality of life with questionnaire (CAHQL). Scale from 0-100 with increasing scale indicating a higher quality of life.
Time frame: at baseline, and 6 and 12 month follow-up
number of participants that receive the emergency preparedness checklist
checklist to understand patient understanding of preparing for adrenal crisis
Time frame: baseline, 6 months, and 12 months after initiation of transition protocol
number of visits a participant requires for acute care
review of patient's use of acute care for adrenal insufficiency. We will count the number of times a participant has to use an ER or urgent care clinic within a 6 month time frame (inquiring at baseline, 6 month, and 12 month visit)
Time frame: baseline, 6 months and 12 months after initiation of healthcare transition protocol
Assess satisfaction and experience survey
assessment of satisfaction and experience survey. 5 question survey of Likert scale ranging 1-5 with 5 indicating very satisfied.
Time frame: after completion of 12 month visit of health care transition protocol
themes regarding CAH healthcare transition
themes from focus groups from adolescents and young adults with CAH guardians/caregivers, and providers
Time frame: up to 24 months
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Jan 2027; primary completion for Dec 2028, 23 months later.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 14, 2026: start Oct 2026 → Jan 2027, primary completion Oct 2028 → Dec 2028 and completion Oct 2029 → Dec 2029.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Adrenal Hyperplasia, Congenital →
University of Alabama at Birmingham →